Literature DB >> 34209586

NLRP3 and Infections: β-Amyloid in Inflammasome beyond Neurodegeneration.

Giulia Sita1, Agnese Graziosi1, Patrizia Hrelia1, Fabiana Morroni1.   

Abstract

Amyloid beta (Aβ)-induced abnormal neuroinflammation is recognized as a major pathological feature of Alzheimer's disease (AD), which results in memory impairment. Research exploring low-grade systemic inflammation and its impact on the development and progression of neurodegenerative disease has increased. A particular research focus has been whether systemic inflammation arises only as a secondary effect of disease, or it is also a cause of pathology. The inflammasomes, and more specifically the NLRP3 inflammasome, are crucial components of the innate immune system and are usually activated in response to infection or tissue damage. Although inflammasome activation plays critical roles against various pathogens in host defense, overactivation of inflammasome contributes to the pathogenesis of inflammatory diseases, including acute central nervous system (CNS) injuries and chronic neurodegenerative diseases, such as AD. This review summarizes the current literature on the role of the NLRP3 inflammasome in the pathogenesis of AD, and its involvement in infections, particularly SARS-CoV-2. NLRP3 might represent the crossroad between the hypothesized neurodegeneration and the primary COVID-19 infection.

Entities:  

Keywords:  Alzheimer’s disease; COVID-19; NLRP3; infections; neurodegeneration; neuroinflammation

Year:  2021        PMID: 34209586     DOI: 10.3390/ijms22136984

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  6 in total

Review 1.  Tangled quest of post-COVID-19 infection-caused neuropathology and what 3P nano-bio-medicine can solve?

Authors:  Nadia M Hamdy; Fatma H Shaker; Xianquan Zhan; Emad B Basalious
Journal:  EPMA J       Date:  2022-06-02       Impact factor: 8.836

2.  PAF Receptor Inhibition Attenuates Neuronal Pyroptosis in Cerebral Ischemia/Reperfusion Injury.

Authors:  Bo Zhao; Yuxiang Fei; Jianping Zhu; Qiyang Yin; Weirong Fang; Yunman Li
Journal:  Mol Neurobiol       Date:  2021-09-25       Impact factor: 5.590

Review 3.  ACE2, Circumventricular Organs and the Hypothalamus, and COVID-19.

Authors:  Wei-Yi Ong; R L Satish; Deron R Herr
Journal:  Neuromolecular Med       Date:  2022-04-22       Impact factor: 4.103

Review 4.  Targeting NLRP3-Mediated Neuroinflammation in Alzheimer's Disease Treatment.

Authors:  Julia Barczuk; Natalia Siwecka; Weronika Lusa; Wioletta Rozpędek-Kamińska; Ewa Kucharska; Ireneusz Majsterek
Journal:  Int J Mol Sci       Date:  2022-08-11       Impact factor: 6.208

5.  Combining Deep Phenotyping of Serum Proteomics and Clinical Data via Machine Learning for COVID-19 Biomarker Discovery.

Authors:  Antonio Paolo Beltrami; Maria De Martino; Emiliano Dalla; Matilde Clarissa Malfatti; Federica Caponnetto; Marta Codrich; Daniele Stefanizzi; Martina Fabris; Emanuela Sozio; Federica D'Aurizio; Carlo E M Pucillo; Leonardo A Sechi; Carlo Tascini; Francesco Curcio; Gian Luca Foresti; Claudio Piciarelli; Axel De Nardin; Gianluca Tell; Miriam Isola
Journal:  Int J Mol Sci       Date:  2022-08-15       Impact factor: 6.208

6.  Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes.

Authors:  Krzysztof Laudanski; Jihane Hajj; Mariana Restrepo; Kumal Siddiq; Tony Okeke; Daniel J Rader
Journal:  Biomedicines       Date:  2021-11-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.